Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) EBITDA (2020 - 2025)

Historic EBITDA for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to -$4.6 million.

  • Cytek Biosciences' EBITDA fell 47340.34% to -$4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.1 million, marking a year-over-year decrease of 4272.91%. This contributed to the annual value of -$4.7 million for FY2024, which is 6283.2% up from last year.
  • As of Q3 2025, Cytek Biosciences' EBITDA stood at -$4.6 million, which was down 47340.34% from -$5.0 million recorded in Q2 2025.
  • Cytek Biosciences' 5-year EBITDA high stood at $9.6 million for Q4 2024, and its period low was -$12.0 million during Q1 2025.
  • Over the past 5 years, Cytek Biosciences' median EBITDA value was -$891000.0 (recorded in 2022), while the average stood at -$1.6 million.
  • As far as peak fluctuations go, Cytek Biosciences' EBITDA surged by 16962.79% in 2022, and later crashed by 82304.15% in 2023.
  • Cytek Biosciences' EBITDA (Quarter) stood at $1.3 million in 2021, then skyrocketed by 169.63% to $3.6 million in 2022, then surged by 63.53% to $5.8 million in 2023, then skyrocketed by 64.58% to $9.6 million in 2024, then tumbled by 148.33% to -$4.6 million in 2025.
  • Its EBITDA stands at -$4.6 million for Q3 2025, versus -$5.0 million for Q2 2025 and -$12.0 million for Q1 2025.